Life Biosciences Appoints Michael Ringel, Ph.D., J.D. As Chief Operating Officer

Jan 27, 2025•7 months ago

Position

Chief Executive Officer

Company

Life Biosciences

Jerry McLaughlin

BostonBiotechnologyHealth Care

Description

Life Biosciences announced the appointment of Michael Ringel, Ph.D., J.D., as Chief Operating Officer. Dr. Ringel, formerly Managing Director and Senior Partner at Boston Consulting Group, brings extensive experience in biotech and pharmaceutical sectors, R&D strategy, and organizational design.

Company Information

Company

Life Biosciences

Location

Boston, Massachusetts, United States

About

Life Bio is a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary partial epigenetic reprogramming platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of age-related diseases with significant unmet medical needs. Life Bio’s lead program, ER-100, is being developed as a gene therapy for optic neuropathies with plans to enter the clinic in 2025. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months